LucentAD Provider Guide
The LucentAD test helps identify whether an individual with concerns about memory or thinking ability is likely or unlikely to have amyloid plaques in the brain, a hallmark of Alzheimer’s disease. The test relies on quantitation of phosphorylated tau protein (p-Tau) in plasma using proprietary single molecule array (Simoa®) technology(1) which provides unprecedented sensitivity and precision for measuring low abundance proteins, such as brain-derived proteins in blood. This readily accessible, noninvasive test enables leveraging a simple blood test for a more informed initial evaluation of patients with memory concerns to help select who would be appropriate for further confirmatory testing for a final diagnosis. Download our guide to learn more.
References:
1. Benedet AL, Brum WS, Hansson O, et al. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimers Res Ther. 2022;14(1):26. Published 2022